Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing stu...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Elsevier
2024-06-01
|
| Collection: | Translational Oncology |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S193652332400072X |